# US 8,278,316 B2 · Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,316 B2
- Document ID: US8278316B2
- Status: Granted
- Kind: B2
- Application number: 13/255,170
- Filed: 2010-03-09
- Published: 2011-12-29
- Granted: 2012-10-02
- Earliest claimed: 2009-03-09
- Assignees: Bristol-Myers Squibb Company
- Inventors: Saleem Ahmad
- Web page: https://patentgrep.com/patent/US8278316B2

## CPC

- C07D 239/36: as doubly bound oxygen atom or as unsubstituted hydroxy radical
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D 239/56: One oxygen atom and one sulfur atom
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

MCHR1 antagonists are provided having the following Formula I: wherein all of the variables are defined herein. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.

## Claims

### Claim 1

A compound having the following Formula I, or pharmaceutically acceptable salt thereof:
wherein,
A1 and A2 are independently C or N;
E is C or N;
Q1, Q2, and Q3 are independently C or N provided that at least one of Q1, Q2, and Q3 is N but not more than one of Q1, Q2, and Q3 is N;
D1 is a bond, —CR8R9X—, —XCR8R9—, —CHR8CHR9—, —CR10═CR10′—, —C≡C—, or 1,2-cyclopropyl;
X is O, S or NR11;
R1, R2, and R3 are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl, —CF3, —OCF3, —OR12, substituted or unsubstituted phenyl, substituted or unsubstituted cycloalkoxy, and —SR12; G is O, S or —NR15;
D2 is substituted or unsubstituted C2 to C4 alkyl, substituted or unsubstituted substituted or unsubstituted C3 to C5 cycloalkyl, substituted or unsubstituted C3 to C5 cycloalkoxy, substituted or unsubstituted C2 to C3 alkyl-C3 to C5 cycloalkyl, substituted or unsubstituted C1 to C3 alkyl-substituted or unsubstituted C3 to C5 cycloalkoxy or when G is —NR15, G and D2 together may optionally form an azetidine, pyrrolidine or piperidine ring;
Z1 and Z2 are independently hydrogen, substituted or unsubstituted C1 to C3 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl, —OCH3, substituted or unsubstituted C3 to C5 cycloalkoxy, halo, —CF3, —OCONR14R14′, —CN, —CONR14R14′, —SOR12, —SO2R12, —NR14COR14′, —NR14CO2R14′, —CO2R12, NR14SO2R12 or —COR12;
R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl, substituted or unsubstituted C3 to C5 cycloalkoxy, —CF3, —SR12, —OCH3, —OCH2CH3, —CN, —CONR14R14′, SOR12, SO2R12, NR14COR14′, NR14CO2R12. CO2R12, NR14SO2R12 and —COR12;
R8, R9, R10, R10′, R11 are independently hydrogen or —CH3;
R12 is substituted or unsubstituted C1 to C4 alkyl or substituted or unsubstituted C3 to C5 cycloalkyl;
R14 and R14′ are independently H, substituted or unsubstituted C1 to C3 alkyl, substituted or unsubstituted C3 to C5 cycloalkyl or R14 and R14′ together with the N to which they are attached form a ring having 4 to 7 atoms; and
R15 is hydrogen or substituted or unsubstituted C1 to C4 alkyl.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R1, R2, and R3 are each independently H, halo, substituted or unsubstituted C3 to C5 cycloalkoxy, or —CF3.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein G is O.

### Claim 4 (depends on 1)

The compound according to claim 1 wherein D2 is —CH2C—.

### Claim 5 (depends on 1)

The compound according to claim 1 wherein Z1 and Z2 are both —CH3 or Z1 is H and Z2 is C3 to C5 cycloalkyl.

### Claim 6 (depends on 1)

The compound according to claim 1 wherein D1 is a bond, —CR8R9X—, —XCR8R9—, —CR10═CR10—, or —C≡C— and X is O, S, —SO2 or —NR11.

### Claim 7 (depends on 1)

The compound according to claim 1 wherein Z1 and Z2 are —CH3 or Z1 is H and Z2 is cyclopropyl.

### Claim 8 (depends on 1)

The compound according to claim 1 having the following Formula Ia:
wherein
R1, R2, and R3 are independently H, halo, C1 to C6 alkyl, or CF3;
A1 is C or N;
A2 is C;
Q1, Q2, and Q3 are independently C or N provided that at least one of Q1, Q2, and Q3 is N but not more than one of Q1, Q2, and Q3 is N;
D1 is a bond, —CR8R9X—, —XCR8R9—, 1,2 cylcopropyl, —CR10═CR10′— or —C≡C—;
X is O, S, —NR11;
R8, R9, R10, R10′, and R11 are each independently H or C1 to C6 alkyl;
R5 is —CH3 or —OCH3, and R6 and R7 are H;
G is O or S;
D2 is —CH2C— or —CH2-cyclobutyl;
Z1 and Z2 are both —CH3, halo, or Z1 is H and Z2 is cyclopropyl.

### Claim 9 (depends on 8)

The compound according to claim 8 wherein Q1 is N and Q2 and Q3 are C.

### Claim 10 (depends on 8)

The compound according to claim 8 wherein Q2 is N and Q1 and Q3 are C.

### Claim 11 (depends on 8)

The compound according to claim 8 wherein Q3 is N and Q2 and Q3 are C.

### Claim 12 (depends on 8)

The compound according to claim 8 wherein D1 is —CH2X— and X is O, S, or NH.

### Claim 13

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the preceding compounds.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 in an amount effective to treat obesity in a patient in need of such treatment together with a pharmaceutically acceptable carrier or diluent.

### Claim 15 (depends on 1)

A pharmaceutical combination comprising a compound according to claim 1 and at least one additional therapeutic agent selected from the group consisting of an anti-obesity agent, an anti-diabetes agent, an anti-anxiety agent, an anti-inflammatory agent or an anti-depressant.
